Invention Grant
- Patent Title: CORE3-MUC1 binding polypeptides and uses thereof
-
Application No.: US17351596Application Date: 2021-06-18
-
Publication No.: US11860165B2Publication Date: 2024-01-02
- Inventor: Hans H. Wandall , Johannes Wirenfeldt Vad Pedersen , Eric Paul Bennett , Henrik Clausen , Ulla Mandel
- Applicant: GO THERAPEUTICS, INC.
- Applicant Address: US MA Cambridge
- Assignee: GO Therapeutics, Inc.
- Current Assignee: GO Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Biospark Intellectual Property Law
- Priority: DK 200970234 2009.11.27
- The original application number of the division: US16161341 2018.10.16
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K16/28 ; G01N33/574 ; C07K16/00 ; C07K14/47 ; C07K14/00

Abstract:
The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.
Public/Granted literature
- US20220065862A1 METHOD FOR EARLY DETECTION OF CANCER Public/Granted day:2022-03-03
Information query